Analysis of the clinicopathologic characteristics of men with prostate cancer undergoing radical prostatectomy in the prostate-specific antigen range of less than 4 ng/ml

Korean Journal of Urology

Volumn 50, Issue 4, 2009, Pages 320-326

  Kwon, Taekmin ^a   Jeong, In Gab ^a   Hong, Jun Hyuk ^a   Ahn, Hanjong ^a   Kim, Choung Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; KOREA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

EID: 65449122764     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2009.50.4.320     Document Type: Article

References (28)

1. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61
2. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Bass RB Jr, et al. Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 1988;139:758-61
3. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70
4. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4
5. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000;55:791-5
6. de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002;97:237-44
7. Postma R, Schroder FH. Screening for prostate cancer. Eur J Cancer 2005;41:825-33
8. Vis AN, Kranse R, Roobol M, van der Kwast TH, Schroder FH. Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int 2002;89:384-9
9. Ku JH. Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer. BJU Int 2006;97:69-72
10. Park HK, Hong SK, Byun SS, Lee SE. T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/ mL in Korean population. Urology 2006;68:85-8
11. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer - part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91:1017-24
12. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51
13. Shekarriz B, Upadhyay J, Bianco FJ Jr, Tefilli MV, Tiguert R, Gheiler EL, et al. Impact of preoperative serum PSA level from 0 to 10 ng/ml on pathological findings and disease-free survival after radical prostatectomy. Prostate 2001;48:136-43
14. Aleman M, Karakiewicz PI, Kupelian P, Kattan MW, Graefen M, Cagiannos I, et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/ml: implications for screening. Urology 2003;62:70-4
15. Berger AP, Volgger H, Rogatsch H, Strohmeyer D, Steiner H, Klocker H, et al. Screening with low PSA cutoff values results in low rates of positive surgical margins in radical prostatectomy specimens. Prostate 2002;53:241-5
16. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350:2239-46
17. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277: 1452-5
18. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94
19. Lee HW, Kwak WK, Choi YH, Choi HY, Lee HM. New thresholds for prostate-specific antigen velocity for prostate cancer screening in Korean patients younger than 60 years old. Korean J Urol 2008;49:113-7
20. Chung JS, Han BK, Jeong SJ, Hong SK, Byun SS, Choe G, et al. Prognostic significance of the tumor volume and tumor percentage for localized prostate cancer. Korean J Urol 2008; 49:1074-80
21. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002;167:103-11
22. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97:1132-7
23. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr, Trock B, et al. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer 2004;101:748-53
24. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 2005;66:156-60
25. Schmid HP, Riesen W, Prikler L. Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004;50:71-8
26. Yang WJ, Lee DH, Chung BH, Cho JS, Choi YD, Kim SJ, et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Urology 2006;67:333-6
27. Crawford ED, Thompson IM. Controversies regarding screening for prostate cancer. BJU Int 2007;100(Suppl 2):5-7
28. Cho JS, Kim SI, Kim SJ, Kim YS, Kim CI, Kim HS, et al. Lowering prostate-specific antigen threshold for prostate biopsy in Korean men: impact on the number needing biopsy. Korean J Urol 2008;49:118-21